基于临床样本免疫组化评估的核仁磷酸蛋白/B23与膀胱癌复发的相关性
Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples.
作者信息
Tsui Ke-hung, Juang Horng-heng, Lee Tsong-hai, Chang Phei-lang, Chen Chien-lun, Yung Benjamin Yat-ming
机构信息
Chang Gung Bioinformatics Center, Department of Urology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kwei-Shan, Taiwan, China.
出版信息
Acta Pharmacol Sin. 2008 Mar;29(3):364-70. doi: 10.1111/j.1745-7254.2008.00747.x.
AIM
To investigate the possible correlation of nucleophosmin/B23 expression with bladder carcinoma recurrence.
METHODS
Surgically-resected bladder tumors staged pTa to pT4 were examined for nucleophosmin/B23 expression by immuno-histochemistry. The study group consisted of 132 consecutive patients surgically treated at Chang Gung Memorial Hospital between December 1998 and November 1999. The mean follow up was 72 months (range: 48-84 months).
RESULTS
Nuclear nucleophosmin/B23 staining was detected in 96% of advanced stage and poorly-differentiated tumors. Higher nucleophosmin/B23 levels were linked to more advanced tumor stages, grades, poor prognosis, and likelihood of recurrence (P<0.05). The Cox multivariate analysis indicated the nucleophosmin/B23 expression as an independent indicator for tumor recurrence (P=0.009).
CONCLUSION
The results suggest that nucleophosmin/B23 is a favorable prognostic indicator for bladder cancer. Nucleophosmin/B23 could be a useful molecular tumor marker for predicting bladder cancer recurrence.
目的
探讨核仁磷酸蛋白/B23表达与膀胱癌复发之间的可能相关性。
方法
采用免疫组织化学法检测手术切除的分期为pTa至pT4的膀胱肿瘤中核仁磷酸蛋白/B23的表达。研究组由1998年12月至1999年11月在长庚纪念医院接受手术治疗的132例连续患者组成。平均随访时间为72个月（范围：48 - 84个月）。
结果
在96%的晚期和低分化肿瘤中检测到核仁磷酸蛋白/B23核染色。核仁磷酸蛋白/B23水平越高，与肿瘤分期越晚、分级越高、预后越差以及复发可能性越大相关（P<0.05）。Cox多因素分析表明核仁磷酸蛋白/B23表达是肿瘤复发的独立指标（P = 0.009）。
结论
结果表明核仁磷酸蛋白/B23是膀胱癌的一个良好预后指标。核仁磷酸蛋白/B23可能是预测膀胱癌复发的有用分子肿瘤标志物。
Zotero 插件